Plasticity of IL-9-secreting T cells T helper subsets, through the secretion of specific cytokines, regulate an array of inflammatory diseases. The differentiation of Th cells into specific cytokine-secreting subsets is highly dependent on the surrounding cytokine environment and the transcription factors expressed within each subset. The Th9 subset, that secretes IL-9 as the defining cytokine, is the latest Th cell population to be described. Our lab recently showed that the transcription factor PU.1 promoted the development of these cells. Both IL-9 and PU.1 expression in T cells are required for maximal infiltration of the lung in models of allergic inflammation. Although, Th9 cells and Th2 cells share obligate transcription factors such as STAT6 and GATA3 and require IL-4 for their development, there is evidence that Th9 cells are a unique Th cell subset. PU.1 represents a switch factor by repressing Th2 cytokines and inducing IL-9. Thus, Th2 cells can acquire IL-9- secreting potential. However, whether the IL-9-secreting Th9 phenotype is stable, or whether Th9 cells may acquire cytokine expression associated with other Th subsets is not known. In this proposal, we will explore Th9 plasticity, and track Th9 cells to assess phenotype switching in vivo. In our first Aim we will determine the stability and plasticity of Th9 cells that either haveor lack expression of PU.1 using in vitro culture systems. In the second Aim we will generate Il9 reporter and lineage-tracing mice and test the presence and fate of IL-9-expressing cells in models of allergic inflammation. Our overall goal for this application is to define the plasticity f Th9 cells in allergic inflammation, and the role of PU.1 in directing this phenotype. The information learned from these studies will provide a greater understanding of the role this subset plays in allergic inflammation, and how targeting this subset, or its functions, might be developed as therapy for allergic disease in humans.

Public Health Relevance

For many years Th2 cells were the only T cells thought to control allergic inflammation. We present preliminary data that a newly described subset of cells called Th9 cells, are also required for allergic inflammation and in this proposal we investigate the stability, development and function. Results from these studies will provide new information about how allergic disease develops, and how T cells could be targeted for the treatment of allergic disease. DESCRIPTION (provided by applicant): Plasticity of IL-9-secreting T cells T helper subsets, through the secretion of specific cytokines, regulate an array of inflammatory diseases. The differentiation of Th cells into specific cytokine-secreting subsets is highly dependent on the surrounding cytokine environment and the transcription factors expressed within each subset. The Th9 subset, that secretes IL-9 as the defining cytokine, is the latest Th cell population to be described. Our lab recently showed that the transcription factor PU.1 promoted the development of these cells. Both IL-9 and PU.1 expression in T cells are required for maximal infiltration of the lung in models of allergic inflammation. Although, Th9 cells and Th2 cells share obligate transcription factors such as STAT6 and GATA3 and require IL-4 for their development, there is evidence that Th9 cells are a unique Th cell subset. PU.1 represents a switch factor by repressing Th2 cytokines and inducing IL-9. Thus, Th2 cells can acquire IL-9- secreting potential. However, whether the IL-9-secreting Th9 phenotype is stable, or whether Th9 cells may acquire cytokine expression associated with other Th subsets is not known. In this proposal, we will explore Th9 plasticity, and track Th9 cells to assess phenotype switching in vivo. In our first Aim we will determine the stability and plasticity of Th9 cells that either haveor lack expression of PU.1 using in vitro culture systems. In the second Aim we will generate Il9 reporter and lineage-tracing mice and test the presence and fate of IL-9-expressing cells in models of allergic inflammation. Our overall goal for this application is to define the plasticity f Th9 cells in allergic inflammation, and the role of PU.1 in directing this phenotype. The information learned from these studies will provide a greater understanding of the role this subset plays in allergic inflammation, and how targeting this subset, or its functions, might be developed as therapy for allergic disease in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31AI100542-02
Application #
8450414
Study Section
Special Emphasis Panel (ZRG1-F07-E (20))
Program Officer
Adger-Johnson, Diane S
Project Start
2012-03-01
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
2
Fiscal Year
2013
Total Cost
$32,229
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Glosson-Byers, Nicole L; Sehra, Sarita; Stritesky, Gretta L et al. (2014) Th17 cells demonstrate stable cytokine production in a proallergic environment. J Immunol 193:2631-40
Jabeen, Rukhsana; Goswami, Ritobrata; Awe, Olufolakemi et al. (2013) Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest 123:4641-53